Sox17-KO Mouse
Common Name
Sox17-KO
제품 ID
S-KO-04424
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-20671-Sox17-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Sox17-KO Mouse (카탈로그 번호 S-KO-04424)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Sox17-KO
품종 계통계통 ID
KOCMP-20671-Sox17-B6J-VA
유전자명
제품 ID
S-KO-04424
유전자 별칭
--
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 1
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000027035
NCBI 전사체 ID
NM_011441
타겟 영역
Exon 5
유효 영역 크기
~1.7 kb
유전자 연구 개요
SOX17, short for SRY-box transcription factor 17, is a pivotal transcription factor. It is crucial in directing the specification and development of the primitive endoderm, primitive germ cells, and definitive endoderm [5]. Subsequently, it is involved in the cardiovascular system and several endoderm-derived organs. It participates in pathways such as Wnt/β -catenin and Notch signaling during development [7]. Genetic models, like KO/CKO mouse models, are valuable for studying its functions.
In colorectal cancer, loss of SOX17 in AKP (Apc -null, KrasG12D and Trp53 -null) tumour-forming organoids reduced their ability to persist in vivo. SOX17 -null tumours had IFNγ -producing effector-like CD8+ T cell infiltrates, while wild-type counterparts had an immune-suppressive microenvironment. SOX17 suppresses tumour cells' ability to sense and respond to IFNγ, preventing anti-tumour T cell responses and engages a fetal intestinal programme to produce immune-evasive LGR5 -tumour cells [1]. In pulmonary hypertension, endothelial SOX17 deficiency in mice, induced by Tie2Cre-mediated Sox17 knockdown or EC-specific Sox17 deletion, led to spontaneously mild pulmonary hypertension and exacerbated hypoxia-induced pulmonary hypertension. Pharmacological inhibition of E2F1, which mediates SOX17 deficiency-induced EC dysfunction, attenuated pulmonary hypertension development [2]. Also, Sox17EC -/- mice had exacerbated chronic hypoxic pulmonary hypertension, while transgenic Tie2 -Sox17 overexpression (Sox17Tg) mice had attenuated symptoms. SOX17 promotes mitochondrial bioenergetics and attenuates PAH via inhibition of HIF2α [3]. SOX17 enhancer knockout in mice reduced lung SOX17 expression, resulting in more severe pulmonary vascular leak and hypoxia-or SU5416/hypoxia-induced pulmonary hypertension [4]. Endothelial knockdown of SOX17 in mice accelerated the progression of SU5416/hypoxia-induced PH, while overexpression attenuated it. SOX17 -associated exosomes blocked HPAECs' proliferation, apoptosis, and inflammation, preventing pulmonary arterial remodeling and PH [6].
In conclusion, SOX17 is essential for normal development and homeostasis. Model-based research, especially using KO/CKO mouse models, has revealed its significant roles in colorectal cancer, where it enables immune evasion, and in pulmonary hypertension, where it affects endothelial function, mitochondrial bioenergetics, and disease progression. Understanding SOX17's functions can provide insights into disease mechanisms and potential therapeutic targets for these diseases.
References:
1. Goto, Norihiro, Westcott, Peter M K, Goto, Saori, Agudo, Judith, Yilmaz, Ömer H. 2024. SOX17 enables immune evasion of early colorectal adenomas and cancers. In Nature, 627, 636-645. doi:10.1038/s41586-024-07135-3. https://pubmed.ncbi.nlm.nih.gov/38418875/
2. Yi, Dan, Liu, Bin, Ding, Hongxu, Fallon, Michael B, Dai, Zhiyu. 2023. E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension. In Hypertension (Dallas, Tex. : 1979), 80, 2357-2371. doi:10.1161/HYPERTENSIONAHA.123.21241. https://pubmed.ncbi.nlm.nih.gov/37737027/
3. Sangam, Shreya, Sun, Xutong, Schwantes-An, Tae-Hwi, Black, Stephen M, Desai, Ankit A. . SOX17 Deficiency Mediates Pulmonary Hypertension: At the Crossroads of Sex, Metabolism, and Genetics. In American journal of respiratory and critical care medicine, 207, 1055-1069. doi:10.1164/rccm.202203-0450OC. https://pubmed.ncbi.nlm.nih.gov/36913491/
4. Walters, Rachel, Vasilaki, Eleni, Aman, Jurjan, Zhao, Lan, Rhodes, Christopher J. 2023. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. In Circulation, 147, 1606-1621. doi:10.1161/CIRCULATIONAHA.122.061940. https://pubmed.ncbi.nlm.nih.gov/37066790/
5. Tan, Daisylyn Senna, Holzner, Markus, Weng, Mingxi, Srivastava, Yogesh, Jauch, Ralf. 2019. SOX17 in cellular reprogramming and cancer. In Seminars in cancer biology, 67, 65-73. doi:10.1016/j.semcancer.2019.08.008. https://pubmed.ncbi.nlm.nih.gov/31419525/
6. Zou, Xiaozhou, Liu, Ting, Huang, Zhongjie, Zhang, Yiwen, Huang, Ping. 2023. SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2206139. doi:10.1002/advs.202206139. https://pubmed.ncbi.nlm.nih.gov/36919784/
7. Zhu, Na, Welch, Carrie L, Wang, Jiayao, Shen, Yufeng, Chung, Wendy K. 2018. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. In Genome medicine, 10, 56. doi:10.1186/s13073-018-0566-x. https://pubmed.ncbi.nlm.nih.gov/30029678/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
